All In Biotech

Drug Trial Radar · NCT01332019

Long-Term Safety and Efficacy Study of Peginterferon Beta-1a

A Dose-Frequency Blinded, Multicenter, Extension Study to Determine the Long-Term Safety and Efficacy of PEGylated Interferon Beta-1a (BIIB017) in Subjects With Relapsing Multiple Sclerosis

Last checked: Nov 20, 2026Latest source record: Jan 13, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,077

Actual

Start

Apr 2011

Primary completion

Oct 2015

Study completion Oct 2015

Sponsor

Lead sponsor
BiogenBiogen (BIIB)
Sponsor type
Industry
First posted
Apr 8, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the long-term safety and tolerability of peginterferon beta-1a (BIIB017) in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment. The secondary objective of this study is to describe long-term multiple sclerosis (MS) outcomes in participants originally treated in Study 105MS301 (NCT00906399) who continue peginterferon beta-1a treatment.

Conditions

  • Relapsing Multiple Sclerosis

Interventions

  • peginterferon beta-1aDrug

    Administered as specified in the treatment arm

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Experiencing Adverse Events (AEs) Serious AEs, and Discontinuations Due to AEsTime frame: up to 4 years
  2. Number of Participants With Potentially Clinically Significant Hematology Laboratory AbnormalitiesTime frame: up to 4 years
  3. Number of Participants With Shifts From Baseline: Liver Function Laboratory ValuesTime frame: Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years
  4. Number of Participants With Shifts From Baseline: Kidney Function and Other Blood ChemistryTime frame: Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years
  5. Number of Participants With Shifts From Baseline: UrinalysisTime frame: Baseline (BIIB017 Treatment Baseline from Study 105MS301) up to 4 years

Locations

151 sites in 26 countries. Site status is shown where the registry gives one.

  • Research Site

    Atlanta, Georgia

  • Research Site

    Lexington, Kentucky

  • Research Site

    Baltimore, Maryland

  • Research Site

    Raleigh, North Carolina

  • Research Site

    Akron, Ohio

  • Research Site

    Cleveland, Ohio

  • Research Site

    Franklin, Tennessee

  • Research Site

    Sint-Truiden, Belgium

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    London, Ontario, Canada

  • Research Site

    Montreal, Quebec, Canada

  • Research Site

    Santiago, Chile

  • Research Site

    Barranquilla, Colombia

  • Research Site

    Bogotá, Colombia

  • Research Site

    Zagreb, Croatia

  • Research Site

    Brno, Czechia

  • Research Site

    Havffov, Czechia

  • Research Site

    Olomouc, Czechia

  • Research Site

    Ostrava, Czechia

  • Research Site

    Ostrava-Vitkovice, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Prague, Czechia

  • Research Site

    Teplice, Czechia

  • Research Site

    Pärnu, Estonia

  • Research Site

    Tallinn, Estonia

  • Research Site

    Tartu, Estonia

  • Research Site

    Amiens, France

  • Research Site

    Bouches-du-Rhone, France

  • Research Site

    Clermont-Ferrand, France

  • Research Site

    Nice, France

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Tbilisi, Georgia

  • Research Site

    Bayreuth, Germany

Showing 40 of 151 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.